Related Experiment Video

Updated: Mar 19, 2026

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
13:18

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

Published on: June 28, 2013

22.3K

[Development of mature cardiomyocytes from human iPS cells: toward cardiac safety assessment]

Yasunari Kanda, Takashi Ashihara, Junko Kurokawa

    Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
    |June 16, 2016
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
    14:03

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

    Published on: March 24, 2023

    2.5K
    Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
    05:38

    Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

    Published on: February 12, 2021

    4.9K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
    13:18

    Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

    Published on: June 28, 2013

    22.3K
    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
    14:03

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

    Published on: March 24, 2023

    2.5K
    Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
    05:38

    Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

    Published on: February 12, 2021

    4.9K

    Related Concept Videos

    iPS Cell Differentiation01:22

    iPS Cell Differentiation

    3.3K
    The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
    3.3K
    Induced Pluripotent Stem Cells01:13

    Induced Pluripotent Stem Cells

    28.5K
    Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
    28.5K

    Articles linked to this work by shared authors, journal, and citation graph.

    BeatVecNet classifies drug-induced contractile phenotypes from beat-gated motion vectors in micropatterned human induced pluripotent stem cell-derived cardiomyocytes.

    British journal of pharmacology·2026

    Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development.

    Regulatory toxicology and pharmacology : RTP·2026

    [Global trends in drug development using alternatives to animal testing].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

    Detection of seizurogenic compounds in human and rat neurons in vitro: A multi-laboratory, multi-model assessment.

    Neurotoxicology·2026

    β-Arrestin-biased activation of type I angiotensin II receptors improves prognosis of murine pediatric heart failure.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

    25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives.

    Frontiers in physiology·2026

    [Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

    [Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

    [A novel human 3D steatohepatitis model recapitulating disease progression for evaluating the efficacy and mechanism of action of MASH therapeutics].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

    [Prediction of drug intestinal absorption and drug-induced intestinal toxicity with the use of human crypt-derived intestinal stem cells and their differentiated cells].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

    [Current progress in brain organoid research for human biology].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

    [Revolutionizing physiology: advances in organ-on-a-chip technology].

    Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us